Ambrosia Biosciences Inc., named after the drink of the Greek gods, secured a $100 million series B to advance its preclinical pipeline of oral obesity drugs. The startup formed after Pfizer Inc.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Colorado drugmaker Ambrosia Biosciences has landed ...

Renovare Therapeutics, Inc., a privately-held biotechnology company pioneering regenerative therapeutics for osteoarthritis, today announced its formal launch from stealth mode and collaboration with ...

Presented at ASCO Annual Meeting, virtual, May 29-31, 2020; World Congress on Lung Cancer, virtual, January 28-31, 2021; ASCO Annual Meeting, virtual, June 4-8, 2021 ...

Old Dog, New Tricks: Oxybutynin for the Treatment of Androgen Deprivation Therapy–Related Vasomotor Symptoms Presented at ASCO Annual Meeting, virtual, May 29-31, 2020; World Congress on Lung Cancer, ...

The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy.

In this interview, Dr. Michelle Fraser highlights how base editing and AI-designed enzymes are expanding therapeutic ...

An updated edition of the Feb. 20, 2026, article. Genomics involves a thorough study of genomes (an organism’s complete set ...

On a conference call with analysts, Gilead walked through how a string of recent deals focused on cancer and autoimmune ...

March 24 (Reuters) - Spanish drugmaker Grifols (GRLS.MC), opens new tab said on Tuesday it has approved a U.S. initial ‌public offering of its U.S. biopharma business. Grifols, which makes drugs using ...

This year, my company celebrates its 50th anniversary as a partner to scientists and innovators. The company was started in 1976, and strategic acquisitions and changes over the past decade, including ...